A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HER2 Positive Locally Advanced or Metastatic Breast Cancer
A Randomized Phase III, Double-Blind, Placebo-Controlled Multicenter Trial of Everolimus in Combination With Trastuzumab and Paclitaxel, as First Line Therapy in Women With HER2 Positive Locally Advanced or Metastatic Breast Cancer
The purpose of this Phase III study was to confirm the value of adding everolimus to weekly paclitaxel and trastuzumab as treatment of HER2-overexpressing metastatic breast cancer.
Inclusion Criteria:
Exclusion Criteria:
Mobile, Alabama 36688, United States
Fullerton, California 92835, United States
Santa Barbara, California 93105, United States
Nashville, Tennessee 37203, United States
CABA, Buenos Aires C1050AAK, Argentina
Rio Negro, Viedma 8500, Argentina
Capital Federal, 1417, Argentina
East Bentleigh, Victoria 3165, Australia
Bogota, Cundinamarca 0000, Colombia
Saint-Herblain Cédex, 44805, France
Heraklion Crete, Greece 711 10, Greece
Shatin, New Territories, Hong Kong, Hong Kong
Hong Kong SAR, Hong Kong
Wilton, Cork, Ireland
Sakyo-ku, Kyoto 606 8507, Japan
Kitaadachi-gun, Saitama 362-0806, Japan
Bunkyo-ku, Tokyo 113-8677, Japan
Chuo-ku, Tokyo 104-8560, Japan